FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381892542> ?p ?o ?g. }

• W4381892542 endingPage "12562" @default.
• W4381892542 startingPage "12544" @default.
• W4381892542 abstract "To achieve the maximum therapeutic effects and minimize adverse effects of trimodal synergistic tumor therapies, a cost-effective programmed photothermal (PTT)-chemodynamic (CDT)-coordinated dual drug chemotherapy (CT) trimodal synergistic therapy strategy in chronological order is proposed. According to the status or volumes of the tumors, the intensity and time of each therapeutic modality are optimized, and three modalities are combined programmatically and work in chronological order. The optimal synergistic therapy begins with high-intensity PTT for 10 min to ablate larger tumors, followed by medium-intensity CDT for several hours to eliminate medium-sized tumors, and then low-intensity coordinated dual drugs CT lasts over 48 h to clear smaller residual tumors. Composite nanoparticles, made of Fe-coordinated polydopamine mixed with copper peroxide as the cores and their surface dotted with lots of doxorubicin-Fe(III)-gossypol infinite coordination polymers (ICPs), have been developed to implement the strategy. These composite nanoparticles show excellent synergistic effects with the minimum dose of therapeutic agents and result in nearly 100% tumor inhibition for mice bearing PC-3 tumors and no observed recurrence within 60 days of treatment. The ratios of the different therapeutic agents in the composite nanoparticles can be adjusted to accommodate different types of tumors with this cost-effective programmed trimodal therapy strategy." @default.
• W4381892542 created "2023-06-25" @default.
• W4381892542 creator A5017100408 @default.
• W4381892542 creator A5026464786 @default.
• W4381892542 creator A5055364261 @default.
• W4381892542 creator A5057018047 @default.
• W4381892542 creator A5057639266 @default.
• W4381892542 creator A5058601096 @default.
• W4381892542 creator A5082924617 @default.
• W4381892542 creator A5088655080 @default.
• W4381892542 date "2023-06-24" @default.
• W4381892542 modified "2023-09-26" @default.
• W4381892542 title "Doxorubicin-Fe(III)-Gossypol Infinite Coordination Polymer@PDA:CuO₂ Composite Nanoparticles for Cost-Effective Programmed Photothermal-Chemodynamic-Coordinated Dual Drug Chemotherapy Trimodal Synergistic Tumor Therapy" @default.
• W4381892542 cites W1972728281 @default.
• W4381892542 cites W1992900987 @default.
• W4381892542 cites W1994023367 @default.
• W4381892542 cites W2027147871 @default.
• W4381892542 cites W2035769780 @default.
• W4381892542 cites W2061719003 @default.
• W4381892542 cites W2112320456 @default.
• W4381892542 cites W2334962863 @default.
• W4381892542 cites W2345476986 @default.
• W4381892542 cites W2516286436 @default.
• W4381892542 cites W2533513686 @default.
• W4381892542 cites W2569530200 @default.
• W4381892542 cites W2591652949 @default.
• W4381892542 cites W2606890488 @default.
• W4381892542 cites W2618974892 @default.
• W4381892542 cites W2728722006 @default.
• W4381892542 cites W2766052526 @default.
• W4381892542 cites W2773814442 @default.
• W4381892542 cites W2883440571 @default.
• W4381892542 cites W2893450414 @default.
• W4381892542 cites W2896998552 @default.
• W4381892542 cites W2901071383 @default.
• W4381892542 cites W2905255974 @default.
• W4381892542 cites W2907959963 @default.
• W4381892542 cites W2921884395 @default.
• W4381892542 cites W2947512353 @default.
• W4381892542 cites W2947802885 @default.
• W4381892542 cites W2952646242 @default.
• W4381892542 cites W2970618535 @default.
• W4381892542 cites W2972083722 @default.
• W4381892542 cites W2982315016 @default.
• W4381892542 cites W2985055119 @default.
• W4381892542 cites W3008370485 @default.
• W4381892542 cites W3020349741 @default.
• W4381892542 cites W3039838730 @default.
• W4381892542 cites W3042575830 @default.
• W4381892542 cites W3044858173 @default.
• W4381892542 cites W3045357625 @default.
• W4381892542 cites W3083094155 @default.
• W4381892542 cites W3089245402 @default.
• W4381892542 cites W3101201118 @default.
• W4381892542 cites W3108412456 @default.
• W4381892542 cites W3112570045 @default.
• W4381892542 cites W3134059314 @default.
• W4381892542 cites W3149546802 @default.
• W4381892542 cites W3153599377 @default.
• W4381892542 cites W3156700126 @default.
• W4381892542 cites W3175629202 @default.
• W4381892542 cites W3211895768 @default.
• W4381892542 cites W3214235689 @default.
• W4381892542 cites W3214416664 @default.
• W4381892542 cites W3216904001 @default.
• W4381892542 cites W4200372495 @default.
• W4381892542 cites W4200586202 @default.
• W4381892542 cites W4200603224 @default.
• W4381892542 cites W4205862902 @default.
• W4381892542 cites W4206426344 @default.
• W4381892542 cites W4210263703 @default.
• W4381892542 cites W4210296165 @default.
• W4381892542 cites W4210401068 @default.
• W4381892542 cites W4210676428 @default.
• W4381892542 cites W4210795205 @default.
• W4381892542 cites W4214723058 @default.
• W4381892542 cites W4214749816 @default.
• W4381892542 cites W4220700123 @default.
• W4381892542 cites W4220993967 @default.
• W4381892542 cites W4224862908 @default.
• W4381892542 cites W4229032930 @default.
• W4381892542 cites W4229373609 @default.
• W4381892542 cites W4280580780 @default.
• W4381892542 cites W4281384078 @default.
• W4381892542 cites W4285384745 @default.
• W4381892542 cites W4289712190 @default.
• W4381892542 cites W4293148591 @default.
• W4381892542 cites W4313312762 @default.
• W4381892542 cites W4313454248 @default.
• W4381892542 cites W4313479403 @default.
• W4381892542 cites W4313522493 @default.
• W4381892542 cites W4313656368 @default.
• W4381892542 doi "https://doi.org/10.1021/acsnano.3c02401" @default.
• W4381892542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37354436" @default.
• W4381892542 hasPublicationYear "2023" @default.
• W4381892542 type Work @default.
• W4381892542 citedByCount "0" @default.
• W4381892542 crossrefType "journal-article" @default.

• next